We found that congestive heart failure was a significant covariate associated with increased mortality among SGLT2 inhibitor users in CML (HR 7.15, 95% CI 3.26, 15.6, p = <0.001) and MM (HR 1.88, 95% CI 1.11, 3.17, p = 0.019), but not AML (HR 1.43, 95% CI 0.77, 2.66, p = 0.261) or MDS (HR 1.18, 95% CI 0.59–2.37, p = 0.64) (data not shown). The gene discussed is SLC5A2; the disease is Miyoshi myopathy.